Theratechnologies, Inc (THTX) - Long-Term Debt to Capital Coefficient
Theratechnologies Inc. (THTX) production facilities in North America focus on HIV therapies and cancer research. This price chart illustrating trading dynamics shows a value of 0.00. The current price is based on the decision to forgo mergers in favor of debt repayment and growth in sales of legacy drugs. High R&D costs and strict FDA oversight protect the firm's position from the emergence of cheap generics.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_THTX_-_Theratechnologies-Inc._-_Long-Term-Debt-to-Capital "THTX: Theratechnologies Long-Term Debt to Capital 07/04/2022 - 10/11/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Theratechnologies Inc. (THTX)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Theratechnologies Inc.|THTX - Long-Term Debt to Capital|Short-Term Debt to Capital theratech.com|THTX - Company Total Debt|Debt to Net Assets Ratio Theratechnologies Inc.|THTX - Company Long-Term Debts|Short-Term Debt Volume Theratechnologies|Quick Liquidity Indicator theratech.com
- net income and valuation ratios data:
General company analysis:Theratechnologies, Inc. - THTX
This ratio determines financial stability by comparing long-term borrowings to equity to assess the business's degree of dependence on external lending. An analysis of the long-term debt-to-equity ratio for Theratechnologies Inc. (THTX) confirms the effectiveness of its manufacturing outsourcing model, which minimizes capital expenditures on equipment, thereby reducing the debt load and enhancing the investment security of the asset.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|SEPN: Long-Term Debt to Equity Ratio|Pieris Corp - Long-Term Loans to Capital Ratio|SVRA: Long-Term Debt to Capital|rigel.com - Long-Term Debt to Capital Coefficient|ANAB (AnaptysBio) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Astria Therapeutics Inc ATXS|Long-Term Debt to Equity enGene Bio (ENGN)|RAPT (rapt.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital JBIO (Aerovate Therapeutics)|Long-Term Debt to Capital aclaristx.com ACRS|KYTX: Long-Term Debt to Equity Ratio|Tiziana Life Sciences Ltd. - Long-Term Loans to Capital Ratio|CABA: Long-Term Debt to Capital|Long-Term Liabilities to Capital Ventyx Biosciences, Inc (VTYX)|AVTX (Avalo Therapeutics, Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio eledon.com (ELDN)|Long-Term Debt to Capital AGEN|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Zura Bio Limited ZURA|ATYR: Long-Term Debt to Capital Ratio|ADAG - Long-Term Debt to Equity|Long-Term Liabilities to Capital ImageneBio Inc|shattucklabs.com (STTK) - Long-Term Debt to Equity|EQ (Equillium) - Long-Term Debt to Equity|Long-Term Debt to Equity Connect Biopharma Holdings|Long-Term Liabilities to Capital Immunic Inc IMUX|Long-Term Debt to Capital ATRA|inflarx.de (IFRX) - Long-Term Indebtedness to Equity|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Ratio of Long-Term Indebtedness to Capital Adicet Bio Inc. (ACET)|Celularity Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital INmune Bio Corporation|Barinthus Biotherapeutics (BRNS) - Long-Term Debt to Equity|KZR - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio SABS|AKTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ENLV|Ratio of Long-Term Indebtedness to Capital q32bio.com|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|EDSA: Long-Term Debt to Capital Ratio|iBio - Long-Term Debt to Capital|Carisma Therapeutics (CARM) - Long-Term Debt to Equity Ratio|XTLB (XTL Biopharmaceuticals, Ltd.) - Long-Term Debt to Equity Ratio|BOLT - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio HCWB|APVO (Aptevo) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital AIM|ADTX (aditxt.com) - Long-Term Debt to Capital Coefficient|GRI Bio Corp - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio XRTX (XORTX Corp)|HIND: Long-Term Debt to Equity Ratio|REVB (revbiosciences.com) - Long-Term Debt to Capital Ratio|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Long-Term Liabilities to Equity SCNI (Scinai Immunotherapeutics Ltd)|CALI (CalciMedica Inc) - Long-Term Debt to Capital|AFMD: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ALLK|Long-Term Debt to Capital hookipapharma.com (HOOK)|Long-Term Debt to Equity IGM Biosciences IGMS|Long-Term Debt to Capital Coefficient ITOS|OCEA - Long-Term Debt to Equity|TC BioPharm Ltd (TCBP) - Long-Term Debt to Equity Ratio|THRD: Long-Term Debt to Capital